Biogen Idec 2Q

2Q Revenues: $1.2 billion (flat)

2Q Earnings: $304.0 million (+3%)

YTD Revenues: $2.4 billion (+4%)

YTD Earnings: $612.8 million (+19%)

Comments: Tysabri revenues were up 28% to $281 million in the quarter. Avonex sales were $659 million (+5%). Rituxan revenues from the joint partnership with Genentech were $216 million in the quarter, down 29% due to ongoing arbitration between Genentech and Hoechst GmbH. Revenues from other products were $16 million, up 36%. Royalties were $29 million in the quarter (-5%).